Lataa...
Hepatitis C virus protease inhibitor-resistance mutations: Our experience and review
Direct-acting antiviral agents (DAAs) for hepatitis C virus (HCV) infection are one of the major advances in its medical treatment. The HCV protease inhibitors boceprevir and telaprevir were the first approved DAAs in the United States, Europe, and Japan. When combined with peginterferon plus ribavi...
Tallennettuna:
| Päätekijät: | , , , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Baishideng Publishing Group Co., Limited
2013
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3870547/ https://ncbi.nlm.nih.gov/pubmed/24379619 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3748/wjg.v19.i47.8940 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|